Esther Navarro-Manzano
Overview
Explore the profile of Esther Navarro-Manzano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
33
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuenca-Guardiola J, de la Morena-Barrio B, Navarro-Manzano E, Stevens J, Ouwehand W, Gleadall N, et al.
iScience
. 2023 Nov;
26(11):108214.
PMID: 37953943
Repetitive sequences represent about 45% of the human genome. Some are transposable elements (TEs) with the ability to change their position in the genome, creating genetic variability both as insertions...
2.
Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro-Manzano E, Blaya Boluda N, de la Morena Barrio P, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345183
Luminal breast cancer (BC) is associated with less immune activation, and the significance of stromal lymphocytic infiltration (sTIL) is more uncertain than in other BC subtypes. The aim of this...
3.
Navarro-Manzano E, Luengo-Gil G, Gonzalez-Conejero R, Garcia-Garre E, Garcia-Martinez E, Garcia-Torralba E, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35625994
While the role of miR-200c in cancer progression has been established, its expression and prognostic role in breast cancer is not completely understood. The predictive role of miR-200c in response...
4.
Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy
Luengo-Gil G, Garcia-Martinez E, Chaves-Benito A, Conesa-Zamora P, Navarro-Manzano E, Gonzalez-Billalabeitia E, et al.
Cell Oncol (Dordr)
. 2019 May;
42(5):627-644.
PMID: 31115881
Purpose: The analysis of breast cancer residual tumors after neoadjuvant chemotherapy (nCT) may be useful for identifying new biomarkers. MicroRNAs are known to be involved in oncogenic pathways and treatment...